You are here:

Forthcoming Submission: sofosbuvir/velpatasvir/voxilprevir (Vosevi)

Indication: Indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults

Drug Details

Drug Name: sofosbuvir/velpatasvir/voxilprevir (Vosevi)
Drug Manufacturer: Gilead Sciences Ltd
BNF Category:
Submission type: Full submission
Patient Interest Group
Submission Deadline:
5/02/2018
SMC Meeting Date: 6/03/2018
Advice Due: 9/04/2018

Back